Meeting
2024 ASCO Genitourinary Cancers Symposium
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.
Authors
Geoffrey Johnson
Mayo Clinic Rochester, Rochester, MN
Geoffrey Johnson , Eva Lengyelova , Luke T. Nordquist , Vikas Prasad , Monique Anderson , Othon Gervasio , Michelle Parker , Robert M. Miller , A. Oliver Sartor , Scott T. Tagawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04868604
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS246)
DOI
10.1200/JCO.2024.42.4_suppl.TPS246
Abstract #
TPS246
Poster Bd #
Q7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer.
First Author: Philip Sutera
Poster
2021 ASCO Annual Meeting
TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer.
First Author: Ben Buelow
Poster
2020 Genitourinary Cancers Symposium
Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell/neuroendocrine prostate cancer.
First Author: Carissa Chu
Poster
2018 ASCO Annual Meeting
A phase I study of 177Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).
First Author: Megan Crumbaker